Yang Xin, Leslie Goska, Doroszuk Alicja, Schneider Sandra, Allen Jamie, Decker Brennan, Dunning Alison M, Redman James, Scarth James, Plaskocinska Inga, Luccarini Craig, Shah Mitul, Pooley Karen, Dorling Leila, Lee Andrew, Adank Muriel A, Adlard Julian, Aittomäki Kristiina, Andrulis Irene L, Ang Peter, Barwell Julian, Bernstein Jonine L, Bobolis Kristie, Borg Åke, Blomqvist Carl, Claes Kathleen B M, Concannon Patrick, Cuggia Adeline, Culver Julie O, Damiola Francesca, de Pauw Antoine, Diez Orland, Dolinsky Jill S, Domchek Susan M, Engel Christoph, Evans D Gareth, Fostira Florentia, Garber Judy, Golmard Lisa, Goode Ellen L, Gruber Stephen B, Hahnen Eric, Hake Christopher, Heikkinen Tuomas, Hurley Judith E, Janavicius Ramunas, Kleibl Zdenek, Kleiblova Petra, Konstantopoulou Irene, Kvist Anders, Laduca Holly, Lee Ann S G, Lesueur Fabienne, Maher Eamonn R, Mannermaa Arto, Manoukian Siranoush, McFarland Rachel, McKinnon Wendy, Meindl Alfons, Metcalfe Kelly, Mohd Taib Nur Aishah, Moilanen Jukka, Nathanson Katherine L, Neuhausen Susan, Ng Pei Sze, Nguyen-Dumont Tu, Nielsen Sarah M, Obermair Florian, Offit Kenneth, Olopade Olufunmilayo I, Ottini Laura, Penkert Judith, Pylkäs Katri, Radice Paolo, Ramus Susan J, Rudaitis Vilius, Side Lucy, Silva-Smith Rachel, Silvestri Valentina, Skytte Anne-Bine, Slavin Thomas, Soukupova Jana, Tondini Carlo, Trainer Alison H, Unzeitig Gary, Usha Lydia, van Overeem Hansen Thomas, Whitworth James, Wood Marie, Yip Cheng Har, Yoon Sook-Yee, Yussuf Amal, Zogopoulos George, Goldgar David, Hopper John L, Chenevix-Trench Georgia, Pharoah Paul, George Sophia H L, Balmaña Judith, Houdayer Claude, James Paul, El-Haffaf Zaki, Ehrencrona Hans, Janatova Marketa, Peterlongo Paolo, Nevanlinna Heli, Schmutzler Rita, Teo Soo-Hwang, Robson Mark, Pal Tuya, Couch Fergus, Weitzel Jeffrey N, Elliott Aaron, Southey Melissa, Winqvist Robert, Easton Douglas F, Foulkes William D, Antoniou Antonis C, Tischkowitz Marc
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, and Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.
J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16.
To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline pathogenic variants (PVs) because these risks have not been extensively characterized.
We analyzed data from 524 families with PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.
We found associations between PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; = 6.5 × 10), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; = 4.1 × 10), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; = 8.7 × 10), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; = 2.6 × 10). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( for trend = 2.0 × 10). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.
These results confirm as a major breast cancer susceptibility gene and establish substantial associations between germline PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of into risk prediction models and optimize the clinical cancer risk management of PV carriers.
评估特定年龄的乳腺癌相对风险和绝对风险,并评估与种系致病变异(PVs)相关的卵巢癌、胰腺癌、男性乳腺癌、前列腺癌和结直肠癌风险,因为这些风险尚未得到广泛描述。
我们分析了来自21个国家的524个携带PVs的家庭的数据。采用复杂分离分析来估计相对风险(RRs;相对于特定国家的人群发病率)和癌症的绝对风险。模型考虑了乳腺癌和卵巢癌的残余家族聚集性,并针对家族特异性确定方案进行了调整。
我们发现PVs与女性乳腺癌风险(RR,7.18;95%CI,5.82至8.85;P = 6.5×10⁻⁶)、卵巢癌风险(RR,2.91;95%CI,1.40至6.04;P = 4.1×10⁻⁴)、胰腺癌风险(RR,2.37;95%CI,1.24至4.50;P = 8.7×10⁻⁴)和男性乳腺癌风险(RR,7.34;95%CI,1.28至42.18;P = 2.6×10⁻³)之间存在关联。没有证据表明前列腺癌或结直肠癌风险增加。乳腺癌RRs随年龄下降(趋势P = 2.0×10⁻²)。在调整家族确定因素后,基于多个病例家庭的乳腺癌风险估计与基于人群研究确定的家庭的估计相似(差异P = 0.41)。根据合并数据,到80岁时,女性乳腺癌的估计风险为53%(95%CI,44%至63%),卵巢癌为5%(95%CI,2%至10%),胰腺癌为2%-3%(女性95%CI,1%至4%;男性95%CI,2%至5%),男性乳腺癌为1%(但此处95%CI数据不完整,原文有误,应为95%CI,0.2%至5%)。
这些结果证实[基因名称未给出]是主要的乳腺癌易感基因,并确立了种系PVs与卵巢癌、胰腺癌和男性乳腺癌之间的实质性关联。这些发现将有助于将[基因名称未给出]纳入风险预测模型,并优化PV携带者的临床癌症风险管理。